Verenium Corp  

(Public, NASDAQ:VRNM)   Watch this stock  
Find more results for VRNM
2.19
+0.04 (1.86%)
May 22 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 2.13 - 2.25
52 week 2.05 - 4.69
Open 2.18
Vol / Avg. 27,715.00/17,690.00
Mkt cap 28.00M
P/E     -
Div/yield     -
EPS -1.41
Shares 12.78M
Beta 1.12
Inst. own 38%
Aug 5, 2013
Q2 2013 Verenium Corporation Earnings Release Add to calendar
Jun 14, 2013
Verenium Corporation Annual Shareholder Meeting and Related Proxy Statement - 1:30PM EDT - Add to calendar
May 9, 2013
Q1 2013 Verenium Corporation Earnings Conference Call
May 6, 2013
Q1 2013 Verenium Corporation Earnings Release
Mar 27, 2013
Q4 2012 Verenium Corporation Earnings Conference Call
Mar 19, 2013
Verenium Corporation at Roth Conference
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '13) 2012
Net profit margin -43.94% 31.96%
Operating margin -27.27% 37.95%
EBITD margin - -12.87%
Return on average assets -27.07% 21.87%
Return on average equity -87.48% 89.60%
Employees 111 -
Carbon Disclosure Rating - -

Address

3550 John Hopkins Ct.
SAN DIEGO, CA 92121
United States - Map
+1-800-5232990 (Phone)
+1-858-4317273 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Discussion Group - Google Finance

Description

Verenium Corporation (Verenium) is an industrial biotechnology company. It develops and commercializes enzymes for use in a range of industrial processes. It manufactures and markets its enzyme products in the fields of animal health and nutrition, grain processing, oilseed processing, oilfield services and other industrial processes, such as pulp and paper and textiles. As of December 31, 2011, it marketed 10 commercial enzyme products, either independently or in collaboration with its partners. In addition, it has developed a pipeline of enzyme product candidates. Its products are organized into five product lines: animal health and nutrition, grain processing, oilseed processing, oilfield services, and other industrial processes. On March 26, 2012, it closed a transaction with DSM Food Specialties B.V. in which it sold its Oilseed Processing business, licensed certain enzymes for use in the food and beverage markets.

Officers and directors

James Henry Cavanaugh Ph.D. Independent Chairman of the Board
Age: 75
Bio & Compensation  - Reuters
James E. Levine President, Chief Executive Officer, Director
Age: 41
Bio & Compensation  - Reuters
Jeffrey G Black Chief Financial Officer, Senior Vice President
Age: 43
Bio & Compensation  - Reuters
Janet S. Roemer Chief Operating Officer, Executive Vice President - Specialty Enzymes Business Unit
Age: 56
Bio & Compensation  - Reuters
Alex A. Fitzpatrick Senior Vice President, General Counsel, Secretary
Age: 45
Bio & Compensation  - Reuters
Holger A Liepmann Director
Age: 61
Bio & Compensation  - Reuters
John F. Dee Independent Director
Bio & Compensation  - Reuters
Peter Johnson Independent Director
Age: 66
Bio & Compensation  - Reuters
Fernand J. Kaufmann Independent Director
Age: 69
Bio & Compensation  - Reuters
Joshua Ruch Independent Director
Bio & Compensation  - Reuters